Gout Therapeutic Market | Top Most Vendors | AstraZeneca plc, Teijin Pharma Ltd., Novartis AG, Takeda Pharmaceutical Company Ltd, Savient Pharmaceuticals and Regeneron Pharmaceuticals

Gout is the most common form of inflammatory arthritis worldwide. It is characterized by pain, redness and tenderness in joints. Gout is crystal-deposition disease due to over production of uric acid above saturation level leading to crystal formation. The incidence of gout has been increasing rapidly worldwide with every six individuals in 1,000 suffering from gout and its related complications based on study conducted by US National Health and Nutrition Examination Surveys (NHANES). Gout conditions are more prevalent in men between ages of 40 to 50 whereas in women chances of developing gout infections increases after onset of menopause. Hence, rising incidence of gout will demand more advanced drugs for treating gout and its related conditions. Gout therapeutic market is expected to witness significant growth due to rise in elderly population, rise in obesity and approval of effective gout therapies.

Gout Therapeutic Market - Competitive Insights:

Numerous multinational as well as local players dominate the global market. Major players comprise GlaxoSmithKline plc; Merck& Co. Inc.; AstraZeneca plc; Teijin Pharma Ltd.; Novartis AG; Takeda Pharmaceutical Company Ltd.; Savient Pharmaceuticals; and Regeneron Pharmaceuticals. Development of new and innovative products, collaborations and strategic acquisitions are some of the strategies acquired by market players to have competitive advantage over their rivals.

To request a sample copy or view summary of this report, click the link below: https://www.crystalmarketresearch.com/report-sample/HC055 .

Gout Therapeutic Market - Trend Analysis:

The global gout therapeutics market is estimated to be around $8 billion by 2025. This market has witnessed tremendous growth in last few years due to preface of various regenerative drugs and escalated acceptance of these biologics for treatment. This can be attributed to their capability to generate potent anti-inflammatory action which speeds up treatment time. Furthermore, many other drugs are currently under clinical trials which are likely to be launched in coming years which will play an important role in the market growth. Rising incidence of gout due to changes in lifestyle, growing alcohol consumption, increasing obesity and ingestion of some specific medications will drive the growth of this market. However, binding regulations and patent expiry of leading drugs will slow down the growth of global market.

Gout Therapeutic Market - Opportunities:

Major players in market are shifting their focus towards more serious gout cases in order to meet unmet medical needs of drugs for effective treatments. NSAIDs and Colchicines are expected to attract large investment due to their increasing adoption and success rate in treating acute as well as chronic gout disease. Many players have collaborated for research and development to develop more efficient drug for the treatment of gout diseases. The market will be dominated by urate lowering agents that has ability to prevent gout disease by blocking genes responsible for gout disease. With FDA approval of Zurampic (in 2015) to reduce uric acid level in blood and other new drugs in clinical trials will bring in huge opportunities for key players in the market.

Gout Therapeutic Market is segmented as follows –

Gout Therapeutic Market - By Product Type:

Colchicines
Corticosteroids
NSAIDs
Urate-lowering Agents

Gout Therapeutic Market - By Disease Condition:

Acute Gout
Chronic Gout

Gout Therapeutic Market - Product Outlook and Trend Analysis:

Non-steroidal anti-inflammatory drugs (NSAIDs) dominates the global market because of superior level of penetration of drug, lower cost, easy availability, and ability to ease pain faster as compared to other available drugs for gout attacks. Urate lowering agents sector is expected to grow at most prominent rate during forecast period. Increasing adoption and innovation of new drugs is likely to enhance market growth. Colchicines occupies significant share in global market, due to their ability to slow down severe inflammatory response by blocking actions of neutrophils responsible for gout attacks. In 2009, FDA approved use of Colchicines for treating gout related fevers.

Gout Therapeutic Market - By Region:

North America - U.S, Canada, Mexico

Europe - Germany, France, UK, Italy, Spain, Rest of Europe

Asia-Pacific - Japan, China, Australia, India, South Korea, Rest of Asia Pacific

Rest of the World - Brazil, South Africa, Saudi Arabia, United Arab Emirates, Others

Gout Therapeutic Market - Regional Outlook and Trend Analysis:

In 2016, the global market was dominated by North America, which can be attributed to various factors such as presence of local primary players, extensive use of gout therapies, and easily availability. U.S. dominated the regional market in 2016, followed by Canada. It is likely to sustain its leading position in the global market during the forecast period, owing to expected launch of new drugs and urate-lowering drugs. In Europe, France and Germany hold highest share for gout disease treatment drugs. Asia-Pacific is projected to witness highest growth rate due to rising incidence of gout disease, increased investments in research for the development of new and alternate therapies. Furthermore, increasing consumption of alcohol and cigarettes, changing life style, and increase in obesity rates is likely to improve growth of gout therapeutics market.

Crystal Market Research published a report on “Gout Therapeutics Market by Product Type and Disease Condition - Global Industry Analysis and Forecast to 2025” released and accessible at: https://www.crystalmarketresearch.com/report/gout-therapeutics-market .

Five Major Market drivers of the Gout Therapeutics Market –

• Demand and popularity of many O-T-C drugs

• Innovation of many urate lowering agents

• Biologics approved for reducing the inflammation of joints

• Increased inclination on regenerative medicines

• More preference given to combination therapies

Gout Therapeutic Market - List of Tables:

Table 1.Global Gout Therapeutics Market, By Product Type ($Million), 2016-2025
Table 3.NSAIDs Market, By Region ($Million), 2016-2025
Table 4.Corticosteroids Market, By Region ($Million), 2016-2025
Table 5.Colchicines Market, By Region ($Million), 2016-2025
Table 6.Urate-lowering Agents Market, By Region ($Million), 2016-2025
Table 10.Global Gout Therapeutics Market, By Disease Condition ($Million), 2016-2025
Table 11.Chronic Gout Market, By Region ($Million), 2016-2025
Table 12.Acute Gout Market, By Region ($Million), 2016-2025
...

Gout Therapeutic Market - List of Figures:

Figure 1.Global Gout Therapeutics Market Share, By Product Type, 2016 & 2025
Figure 2.Gout Therapeutics Market Share, By Disease Condition, 2016 & 2025
Figure 3.Gout Therapeutics Market, By Region, 2016, ($Million)
Figure 4.Takeda Pharmaceutical Company Ltd.: Net Revenues, 2014-2016 ($Million)
Figure 5.Takeda Pharmaceutical Company Ltd.: Net Revenue Share, By Segment, 2016
Figure 6.Takeda Pharmaceutical Company Ltd.: Net Revenue Share, By Geography, 2016
Figure 7.Novartis: Net Revenues, 2014-2016 ($Million)
Figure 8.Novartis: Net Revenue Share, By Segment, 2016
Figure 9.Novartis: Net Revenue Share, By Geography, 2016
...

Key Findings of the Research Study:

• NSAIDs segment dominated the global market with almost two-fourth share in 2016, due to low cost and ability to produce strong anti-inflammatory response.

• Colchicine segment accounted for significant market share in 2016, due their ability to inhibit inflammatory action of Neutrophils.

• Chronic gout dominated the global market in 2016 owing to high prevalence of chronic gout infections worldwide.

• U.S. dominated the global market in 2016, due to high adoption of advanced drugs and treatment methods.

• Asia-Pacific is poised to grow at a high CAGR during the forecast period, owing to increase in population base suffering from gout infections and rise in adoption rate of gout therapies.

Discuss our expert team: https://www.crystalmarketresearch.com/send-an-enquiry/HC055 .

Continued…

About Crystal Market Research:

Crystal Market Research is a U.S. based market research and business intelligence company. Crystal offers one stop solution for market research, business intelligence, and consulting services to help clients make more informed decisions. It provides both syndicated as well as customised research studies for its customers spread across the globe. The company offers market intelligence reports across a broad range of industries including healthcare, chemicals & materials, technology, automotive, and energy.

Contact Us:
Judy
304 South Jones Blvd, Suite 1896,
Las Vegas NV 89107,
United States
Toll Free: +1-888-213-4282
Email: sales@crystalmarketresearch.com

This release was published on openPR.